Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients
| Autor: | Jean-Pierre Aboulker, Christine Durier, Odile Launay, Séverine Mercier-Delarue, François Simon, Sophie Matheron, Nathalie Colin de Verdiere, Sophie Even, Vincent Meiffrédy, Assia Samri, Jean-Michel Molina, Brigitte Autran |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Adult Male Enzyme-Linked Immunospot Assay Adolescent T-Lymphocytes 030231 tropical medicine Immunology Yellow fever vaccine HIV Infections Antibodies Viral 03 medical and health sciences Interferon-gamma Young Adult 0302 clinical medicine Neutralization Tests Yellow Fever Immunology and Allergy Medicine Humans Prospective Studies Young adult Prospective cohort study biology business.industry Immunogenicity Yellow fever Yellow Fever Vaccine virus diseases Middle Aged medicine.disease Virology Antibodies Neutralizing Vaccination 030104 developmental biology Infectious Diseases Immunization biology.protein Female Antibody business medicine.drug |
| Zdroj: | AIDS (London, England). 32(16) |
| ISSN: | 1473-5571 |
| Popis: | The objective of this study is to investigate immunogenicity and safety of the yellow fever vaccine (YFV) in HIV-infected (HIV+) patients with high CD4 T-cell counts.In this prospective, comparative study of YFV-naive adults: 40 HIV+ under antiretroviral therapy (ART) with CD4 T-cell count above 350 cells/μl and plasma HIV-RNA less than 50 copies/ml for at least 6 months and 31 HIV-negative (HIV-) received one injection of the YF-17D strain vaccine.Serologic response was assessed by using a plaque reduction neutralizing test and YFV-specific T cells by using an INFγ-Elispot assay.YFV was well tolerated in both groups. Most participants had asymptomatic YFV viremia at day (D) 7 after vaccination (77% of HIV- and 82% of HIV+, P = 0.58), with higher plasma level of YFV RNA in HIV+ than in HIV- (median 2.46 log10 copies/ml (range: 1.15-4.16) and 1.91 log10 copies/ml (1.15-3.19), respectively, P = 0.011). A significant but transient decrease in CD4 cell counts was seen at D7 in both groups, more pronounced in HIV- than in HIV+ patients (-261.5 versus -111.5 cells/μl, respectively, P = 0.0003), but no HIV breakthrough was observed in plasma. All participants developed protective neutralizing antibody levels from D28 and up to 1 year after injection. At D91, fewer HIV+ than HIV- participants exhibited YFV T-cell response (20 versus 54%, respectively, P = 0.037).At 1 year, YFV was immunogenic and well tolerated in HIV-infected adults under ART with CD4 T-cell counts above 350 cells/μl. However, a lower immunity of YFV T cells in HIV-infected patients was observed as compared with HIV- participants.NCT01426243. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|